N@N

DYAX CORP (NASDAQ:DYAX), Down By 10.13% ($0.16) From $1.580 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearis

^{Published on 2012-02-10 13:41:03 - WOPRAI}
 

February 10, 2012 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Wednesday, January 25th 2012 stating that DYAX CORP (NASDAQ:DYAX) was expected to go Down due to the Bearish conditions presented in the following report. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=dyax&id=235141

At the time this story was written, DYAX CORP (NASDAQ:DYAX) is Down By $0.16 (10.13%) since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following specific fundamental or technical events may follow a predictable pattern. Many companies stock price histories show random or unpredictable movements around certain events. But some seem to repeat the same pattern quarter after quarter, year after year. We use powerful computers to uncover those events and correlations to generate predictions with high probabilities of generating very specific returns within very specific time periods.

The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

DYAX CORP (NASDAQ:DYAX) - Dyax Corp., a biopharmaceutical company, engages in the discovery, development, and commercialization of biotherapeutics for unmet medical needs with an emphasis on inflammatory and oncology indications. The company utilizes its proprietary drug discovery technology, known as phage display, to identify antibody, small protein, and peptide compounds for clinical development. It commercializes its lead product candidate, DX-88, a recombinant small protein, under the KALBITOR (ecallantide) name for treatment of acute attacks of hereditary angioedema in patients 16 years of age and older. The company is also developing DX-88 for the reduction of blood loss during surgery in collaboration with Cubist Pharmaceuticals, Inc.; and for the treatment of retinal diseases in collaboration with Fovea Pharmaceuticals SA, as well as for the treatment of angiotensin converting enzyme inhibitor-induced angioedema and other angioedema indications. Its other discovery and development programs include DX-2240, an antibody that targets Tie-1 receptor on tumor blood vessels; and DX-2400 antibody, an inhibitor that inhibits matrix metalloproteinase 14 on tumor cells and tumor blood vessels. In addition, the company provides patent licenses to other biopharmaceutical and pharmaceutical companies to use its phage display patents, to discover and develop biologic compounds for use in specified fields; offers library licenses to use its phage display libraries in connection with their internal therapeutic development programs; and performs funded research for various collaborators. Further, it has co-development collaboration agreements with Athera Biotechnologies AB, Commonwealth Scientific and Industrial Research Organisation, Defiante Farmaceutica, S.A. and Syntonix Pharmaceuticals, Inc. Dyax Corp. was founded in 1989 and is headquartered in Cambridge, Massachusetts.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor market-maker surveillance system tracking Level II market-makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 30 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies specifically for this report, but may have been compensated up to $1,200 per month in the past for unrelated data or report services. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net